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Introduction
Currently, we use the classification criteria for antiphos-
pholipid syndrome (APS) formulated during the consen-
sus conference in Sapporo and revised in Sydney [1].
Classification criteria for definite APS are met when at
least one clinical criterion (thrombosis or pregnancy
morbidity) and one laboratory criterion (lupus anticoag-
ulant (LAC), anticardiolipin antibodies (aCL) or beta2-
glycoprotein I antibodies (ab2GPI)) are present. Positive
laboratory tests should be confirmed 12 weeks after the
initial testing. Recommendations published in 2009 and
2014 by the Scientific Standardisation Subcommittee
(SSC) on Lupus Anticoagulant/Phospholipid Antibodies
for the detection of LAC and aCL/ab2GPI antibodies
have proven useful working documents on how to per-
form the assays [2,3]. In addition, since 2006 a huge
number of publications on which laboratory tests to use
have been published, addressing the sensitivity and speci-
ficity of aCL and ab2GPI, level for positivity, isotype,
other antiphospholipid antibodies (aPL), etc. There is
contrasting information in these studies, which may be
confusing for the end user. This is a major concern of
this Subcommittee, and therefore the past and present
Chairs decided to summarize the consensus on labora-
tory criteria, with a focus on what has changed since
2006.
Clarification of the recommendations summarized in
Table 1
Lupus anticoagulant
LAC persists as a well-established thrombotic risk factor,
illustrated in many studies and often based on the meta-
analysis of Galli [4,5]. However, in this meta-analysis no
distinction was made between isolated LAC and LAC
associated with positivity in ELISA tests. When isolated
LAC only is considered, the risk of thrombosis is low [6].
For LAC we rely on a combination of two phospholipid
(PL)-dependent clotting assays as no single test has suffi-
cient sensitivity and specificity [2]. With all the disadvan-
tages of LAC testing [7,8], the search for better-performing
Table 1 Recommended laboratory testing for the antiphospholipid
syndrome
1. Lupus anticoagulant (LAC) present in plasma detected
according to the Scientific Standardisation Subcommittee (SSC)
on Lupus Anticoagulant/Phospholipid Antibodies
recommendations [2]
2. b2GPI-dependent anticardiolipin antibodies (aCL) of IgG/IgM
isotype in plasma or serum, present at higher levels (> 99th
percentile of normal controls), measured by solid phase assays
(ELISA or automated systems), according to the SSC on Lupus
Anticoagulant/Phospholipid Antibodies recommendations [3]
3. b2GPI-antibodies (ab2GPI) of IgG/IgM isotype in plasma or
serum, present at higher levels (> 99th percentile), measured by
solid phase assays (ELISA or automated systems), according to
the SSC on Lupus Anticoagulant/Phospholipid Antibodies
recommendations [3]
4. LAC, aCL and ab2GPI should be positive on two or more
occasions at least 12 weeks apart [1–3]
5. Laboratory results need to be reviewed and interpreted in a
collaboration between a clinical pathologist and a clinician who
is skilled at interpreting the data
6. Comprehensive aPL testing (LAC, aCL, and ab2GPI IgG and
IgM) should be carried out as triple aPL-positive patients are at
high risk of thrombosis or aPL-related pregnancy morbidity.
7. Other antiphospholipid antibody tests are not recommended yet
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coagulation assays in LAC continues. Functional assays
that can discriminate between thrombosis-related and non-
thrombosis-related aPL have been described, including
thrombin generation assays [9,10]. Thrombin generation
depends on the presence of negative phospholipid surfaces,
and one single test may provide more accurate information
than the multitude of clotting assays required in LAC test-
ing today. However, these assays are not robust enough to
use in routine testing yet. So, the multiple-step procedure,
with screening, mixing and confirmation steps, is still
applied [1,2]. LAC testing in patients under treatment with
anticoagulation therapy may cause erroneous results, but
this is beyond the scope of this paper and will be addressed
in a separate SSC recommendation.
Anticardiolipin and beta2-glycoprotein I antibodies
In the Sydney criteria ab2GPI was added as an extra lab-
oratory criterion and not as a substitute for aCL. Conse-
quently, we recommend performing all three tests (LAC,
aCL and ab2GPI) to diagnose APS [1–3].
Traditionally, aCL and ab2GPI are detected by ELISA
[1]; however, recently automated platforms with variations
of the solid phase (e.g. magnetic microparticles and micro-
spheres) and various detection systems (e.g. chemilumi-
nescense, flow cytometry and multiplex systems) have been
introduced into the market [11–16]. Automated systems
have the advantage that the working conditions are more
harmonized, providing a strict protocol on how to perform
the assay, which may reduce the inter-laboratory variation
[17]. They perform aCL and ab2GPI IgG/IgM assays more
rapidly and are less labor intensive, providing the four
results at once, instead of running multiple ELISAs.
Although it is not specified in the Sydney criteria that
aCL should be b2GPI dependent, it is mandatory to
avoid detection of non-cofactor-related aCL associated
with infections or several drugs [1,3]. Specificity of aCL
assays depends on the source and amount of b2GPI
[18,19]. After the discovery of b2GPI as the most impor-
tant cofactor for aPL, the ab2GPI assay was thought to
be more specific and more reliable for standardization. A
debate started on the role of aCL, but soon it became
clear that ab2GPI assays suffer from the same problems
of standardization and that methodologically correct
b2GPI-dependent aCL assays do have diagnostic value,
with identical sensitivities and specificities to ab2GPI
assays [16,20]. Not surprisingly, because all these assays
use b2GPI antigen, a high correlation is observed between
aCL and ab2GPI levels [13,16].
A major problem is the high variability between the
commercially available aCL and ab2GPI assays in classi-
fying samples as positive or negative and in antibody
level. In external quality control exercises and using
human monoclonal antibodies with different reactivity
towards b2GPI discriminating detection of open and
closed confirmation of b2GPI, differences were
demonstrated in commercially available ab2GPI IgG
ELISA assays, as well as in automated systems [21–23].
The role of IgM has been discussed based on a stronger
association of IgG with thrombosis compared with IgM
[4,24], whereas for pregnancy morbidity the role of IgM
should be further established [19]. A more recent system-
atic review of the literature on the role of IgM aPL was
not able to give a clear answer [25]. More significant IgG
correlations with thrombosis were confirmed; however,
significant associations for IgM were also found, but with
corresponding IgG. Unavailability of paired results of
IgG and IgM for each separate patient hampered the
evaluation of added value of IgM and the question of
how many APS patients would be missed upon omission
of IgM could not be answered [25]. We advise continued
measurement of IgG and IgM; moreover, the presence of
aCL and ab2GPI of the same isotype reinforces the clini-
cal probability of APS [26]. The significance of IgA aCL
and ab2GPI remains controversial [1,3]. Future studies
are needed to investigate the role of IgA in APS-asso-
ciated clinical events.
Lacking an international standard, we still have to
report a level derived from the calibration curve, which
can differ widely between systems [7]. Although useful for
the clinician and making positive and negative results
interchangeable between different systems, semiquantita-
tive results (low-medium-high) are difficult to define. Each
test result above the cut-off value calculated as higher than
the 99th percentile, should be regarded as positive [3].
However, lower levels of antibodies are observed in certain
clinical settings, especially pregnancy morbidity [27,28].
The clinical relevance of aCL and/or ab2GPI results that
are below the 99th percentile needs to be studied and bet-
ter defined using standardized laboratory methods.
Antibody profiles
To characterize the patient’s antibody profile, all three
tests should be performed, preferentially in the same sam-
ple. Antibody profiles were already introduced into the
Sydney criteria, categorizing patients into groups with
one or more laboratory criteria (in any combination) pre-
sent [1]. A modification of this categorization was
described, taking into account the type and the number
of positive tests [29]. Evidence has shown that patients
with more than one positive test, and particularly those
patients with triple positivity (LAC and aCL and
ab2GPI; same isotype), show the strongest association
with thrombotic and obstetric APS [30,31]. Moreover,
clinical studies confirm that triple positivity in APS
patients and carriers indicates a high risk of recurrence of
thrombosis or development of a first thrombosis, respec-
tively [32,33]. Double-positive patients (mostly LAC nega-
tive) are generally at lower risk. Probably, in these
patients ab2GPI level is insufficient to induce LAC posi-
tivity [34]. Single-positive patients (LAC, aCL or ab2GPI)
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are less likely to develop aPL-related events [1]. However,
in obstetric APS and in arterial thrombosis (myocardial
infarction and stroke) being LAC positive, independent
of the associated other aPL, was the main predictor for
thrombotic events and adverse pregnancy outcome
[35,36]. Clinical studies should report results on patient
populations with homogeneous aPL profiles.
In making antibody profiles, we should be aware of
inter-assay and inter-laboratory variability and the perfor-
mance characteristics of the assays: a sample assigned
positive in one assay does not automatically test positive
in an assay from a different manufacturer or in another
laboratory [7,22]. Agreement for triple positivity between
systems needs to be further studied, but looks promising
[37,38]. Testing with other methods can be useful in
patients with high clinical suspicion. Because interpreta-
tion of aPL results may be challenging, test results should
always be related to clinical symptoms and an interaction
between the laboratory and clinician is essential.
Other antiphospholipid antibodies
The b2GPI domain I antibodies (aD1), a subgroup of IgG
ab2GPI, are strongly associated with thrombosis [39,40].
So far, research assays have been applied to detect these
antibodies, but recently a commercial chemiluminescence
immunoassay assay (CIA) has become available to detect
aD1. Several studies with the CIA aD1 assay confirmed
high odds ratios for thrombosis and the role of aD1 in risk
stratification [41–44]. Correlating to the higher risk, aD1
IgG are mainly present in triple-positive patients, also
showing higher levels [42,43]. A limited number of studies
have evaluated whether the aD1 are independent risk fac-
tors for thrombosis, and showed that aD1 had no added
value to the current aPL panel [42,45]. So far, aD1 mea-
sured by the only available commercial assay should be
considered as a confirmation of the higher thrombotic risk,
rather than a candidate for replacement of the ab2GPI.
Recently it was shown, using the monoclonal antibodies
that detect the percentage of exposure of epitope G40-R43
on domain I in full-length beta2GPI, that in these commer-
cial aD1 assays, not all epitopes on domain I are exposed.
However, we cannot exclude that other epitopes on
domain I may play a role. Antibodies to other domains of
b2GPI are not associated with thrombotic events [46].
Antibodies to phosphatidylserine/prothrombin (aPS/
PT) have been investigated in addition to the current aPL
panel in APS patients with favorable results, regarding
their potential diagnostic value [47]. Mainly associated
with LAC, their additional value in APS diagnosis needs
to be confirmed [48].
Repeat testing
Although triple-positive patients have a persistently
abnormal antibody profile on follow-up testing after
12 weeks [49], we still recommend re-testing for confirma-
tion after 3 months. This was originally meant to avoid
over-diagnosis by classification of transient positivity of
antibodies as APS [1,2]. However, reproducing the same
test results as for the initial positive test after 3 months
ensures the reliability of the positive test, which is impor-
tant in the context of poor standardization and interfer-
ences with effect on the test result [7,49].
In conclusion, the joint efforts of independent organiza-
tions are contributing to an improved standardization of
the assays and diagnosis of APS. The SSC on Lupus
Anticoagulant/Phospholipid Antibodies continues to
work on improvement of the detection of aPL.
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